Navigation Links
Aoxing Pharmaceutical Company Announces Management Change
Date:7/6/2012

JERSEY CITY, N.J., July 6, 2012 /PRNewswire/ -- Aoxing Pharmaceutical Company, Inc. (NYSEAMEX: AXN), a specialty pharmaceutical company specializing in research, development, manufacturing and distribution of a range of narcotics and pain-management products, today announced that Mr. Bob Yunjun Ai has resigned as Chief Financial Officer of the Company to pursue other business interests, effective as of July 1, 2012. The Company expresses its appreciation for Mr. Ai's significant contributions to the Company and wishes him the best in his future endeavors. 

The Company has appointed Mr. Guoan Zhang as acting Chief Financial Officer to replace Mr. Ai. Mr. Zhang was Senior Vice President of Finance prior to the appointment. He joined the Company in 1998 and held various positions in the finance function. Mr. Zhang is a China CPA. 

The Company also appointed Ms. Guirong Zhou as Vice President of R&D to lead the R&D function. Ms. Zhou has in depth experience in pharmaceutical research and is responsible for our new drugs applications. Ms. Zhou has around 30 years of research and product development experience and she obtained a lot of awards and achievements in the pharmaceutical area. Ms. Zhou is a pharmaceutical expert in research centers and had worked for Shijiazhuang Pharmaceutical Group and other major pharmaceutical companies.

About Aoxing Pharmaceutical Company, Inc. Aoxing Pharmaceutical Company, Inc. is a US incorporated specialty pharmaceutical company with its operations in China, specializing in research, development, manufacturing and distribution of a variety of narcotics and pain-management products.

For more information, please visit: www.aoxingpharma.com.

Safe Harbor Statement from Aoxing Pharmaceutical Company, Inc. Certain statements made in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties that may cause actual results to differ materially from those set forth in these statements. All forward-looking statements included herein are based upon information available to the Company as of the date hereof and, except as is expressly required by the federal securities laws, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason. To the extent that any statements made here are not historical, these statements are essentially forward-looking. The Company uses words and phrases such as "guidance," "forecasted," "projects," "is expected," "remain confident," "will" and/or similar expressions to identify forward-looking statements in this press release. Undue reliance should not be placed on forward-looking information. The economic, competitive, governmental, technological and other risk factors identified in the Company's filings with the Securities and Exchange Commission, specifically, Item 1A, "Risk Factors," in the Form 10-K for the year ended June 30, 2011, may cause actual results or events to differ materially from those described in the forward-looking statements in this press release. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise.

Company contact: Vicky Zhang 646-367-1747 Investor.relations@aoxingpharma.com 


'/>"/>
SOURCE Aoxing Pharmaceutical Company, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Report Presents a Framework for Successful New Oncology Product Launches in the Pharmaceutical Sector
2. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
3. Pharmaceutical Industry Service Company Awarded The UKs Most Prestigious Business Accolade in Recognition of Outstanding Achievement in International Trade
4. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
5. Simcere Pharmaceutical Group to Announce First Quarter 2012 Financial Results on Wednesday, May 9, 2012
6. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
7. Thomson Reuters Launches New Mobile Oncology Decision Support Solution for R&D Pharmaceutical Leaders
8. Amgen to Acquire Mustafa Nevzat, a Leading Privately Held Turkish Pharmaceutical Company
9. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
10. Icahn Issues Statement Regarding Amylin Pharmaceuticals
11. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2017)... June 30, 2017  AVACEN Medical (AVACEN) announced the publication of ... describes the use of its AVACEN Treatment Method to ... fibromyalgia. ... AVACEN Medical ... chronic widespread pain. It affects approximately 200 to 400 million people worldwide ...
(Date:6/27/2017)...  Therapix Biosciences Ltd. (Nasdaq: TRPX ) ... development of cannabinoid-based drugs, today announced that the Company ... New York, NY on Wednesday, ... offering (IPO) of American Depository Shares (ADSs) listed on ... Dr. Elran Haber, Ph.D., Chief Executive Officer of Therapix, ...
(Date:6/20/2017)... Netherlands and LAGUNA HILLS, Calif. ... the presentation of new data that validate the use ... risk stratify patients with multiple myeloma (MM). In a ... the European Hematology Association (EHA) in Madrid, ... value of MMprofiler for identifying high-risk elderly patients. ...
Breaking Medicine Technology:
(Date:7/17/2017)... KOREA (PRWEB) , ... July ... ... receipt of CE marking for its faster PICOPLUS 450 ps pulse width ... picosecond- and nanosecond-domain 1,064-nm neodymium-doped yttrium-aluminum-garnet lasers in tissue-mimicking phantom’ featured in ...
(Date:7/17/2017)... ... July 17, 2017 , ... Summer camp season ... to ensure children are protected from Lyme and other tick-borne diseases. , With ... an increased risk not only for the tick-borne illness, but for its various ...
(Date:7/17/2017)... ... July 17, 2017 , ... HMP , a ... with the Texas Academy of Family Physicians (TAFP) for the 6th ... at the Hyatt Regency Dallas in Dallas, Texas.     , CRS and TAFP will ...
(Date:7/17/2017)... ... 17, 2017 , ... Jordan Search Consultants (JSC), a national ... for Springfield Clinic’s Chief Executive Officer (CEO) in Springfield, IL. Working with JSC ... with more than 30 years of experience, as the new CEO. , ...
(Date:7/17/2017)... Aliso Viejo, CA (PRWEB) , ... July 17, 2017 , ... ... Pro X. These minimalistic layouts can be used to complement vlogs, professional productions, and ... using the click of a mouse. Manipulate camera controls to make beautiful and unique ...
Breaking Medicine News(10 mins):